T1	Premise 731 902	Overall, patients receiving goserelin alone showed a marked improvement or less deterioration in QOL measures over the first 6 months than those patients treated with CMF.
T2	Premise 903 1010	There were no differences at 3 years after random assignment according to treatment except for hot flashes.
T3	Premise 1011 1121	As reflected in the hot flashes scores, patients in all three treatment groups experienced induced amenorrhea,
T4	Premise 1122 1225	but the onset of ovarian function suppression was slightly delayed for patients receiving chemotherapy.
T5	Premise 1226 1460	Younger patients (< 40 years) who received goserelin alone returned to their premenopausal status at 6 months after the cessation of therapy, while those who received CMF showed marginal changes from their baseline hot flashes scores.
T7	Claim 1461 1812	Age-adjusted risk profiles that consider patient-reported outcomes enable patients to adapt to their disease and treatment, such as considering the trade-offs between delayed endocrine symptoms, but higher risk of permanent menopause with chemotherapy, and immediate but reversible endocrine symptoms with goserelin, in younger premenopausal patients.
R1	Support Arg1:T5 Arg2:T7	
R2	Partial-Attack Arg1:T4 Arg2:T3	
R3	Support Arg1:T3 Arg2:T7	
R4	Support Arg1:T2 Arg2:T7	
R5	Support Arg1:T1 Arg2:T7	
